CD388
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 14, 2022 (NCT05285137)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300085 | Phase 1 | Nov 8, 2025 | Cidara Therapeutics |
| NCT07225959 | Phase 2 | Oct 29, 2025 | Cidara Therapeutics |
| NCT07159763 | Phase 3 | Sep 25, 2025 | Cidara Therapeutics |
| NCT06609460 | Phase 2 | Sep 20, 2024 | Cidara Therapeutics |
| NCT05619536 | Phase 1 | Oct 18, 2022 | Altasciences Company Inc., Cidara Therapeutics, Janssen Pharmaceutica NV |
| NCT05523089 | Phase 2 | Aug 30, 2022 | Cidara Therapeutics, hVIVO Services Limited, Janssen Pharmaceutica NV |
| NCT05285137 | Phase 1 | Mar 14, 2022 | Altasciences Company Inc., Cidara Therapeutics, Janssen Pharmaceutica NV |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cidara Therapeutics | For profit | 7 | 7 | 3 | 2022 |
| Janssen Pharmaceutica NV | For profit | 3 | 0 | 2 | 2022 |
| Altasciences Company Inc. | For profit | 2 | 0 | 1 | 2022 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1